{"ticker": {"uuid": "621fe7b6-7088-42ee-8897-c0a44458e7b3", "symbol": "AZN", "name": "AstraZeneca PLC", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today", "summary": "AstraZeneca (AZN) shares dipped 1.35% today, slightly underperforming the broader market due to a confluence of factors including ongoing concerns about its China subsidiary and recent analyst downgrades. Despite these short-term pressures and valuation scrutiny, the company main", "url": "https://www.kavout.com/market-lens/why-did-astrazeneca-azn-stock-dip-more-than-the-market-today", "source_name": "Kavout", "published_at": "2026-06-21T05:09:24", "published_display": "21 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNalVkSVBsa1oyTE1DU25VZjlQNWNrWkFTOFRFMEItWjFzaThNMk92WkRydTVCbnBhOFdCUGN0LU1TYUFyd0RfQml6eWdzM1YtV3BGdGZnQ1h6cHlMd1R2U2FtREI4dXhyTktUWW0xNmVXM1lWTzhlN2tleTN2UWktMmNXclE2SWFoT3NZVnh0emctblFYU2c?oc=5", "source_name": "Market source", "published_at": "2026-06-20T02:07:00+00:00", "published_display": "20 Jun 2026 02:07", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Takes Oral GLP 1 Drug Elecoglipron Into Phase III", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-takes-oral-170935835.html", "source_name": "Simply Wall St.", "published_at": "2026-06-19T17:09:35+00:00", "published_display": "19 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T16:33:51+00:00", "published_display": "19 Jun 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOYzJ1VmltcFhibVVwU0stc19wdXd3Z0tKdU1wTUFrcjEzeTI2RnhHc3gxX3YybVZJSVBhQmVreldvLU9SeHVmLTNTTjU0WlpZSDA0aWtzWFhzWW1RS01VYzJTUE5DUDM4RGFtZWFrcWQ1NnFWakZuZUw0VTA4WWFxRWg1X3l0Y2hDZEQ1ZzZNNkFFT1R2ZlYyLVFwUHk?oc=5", "source_name": "Market source", "published_at": "2026-06-19T13:09:58+00:00", "published_display": "19 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AZN News | ASTRAZENECA PLC (NYSE:AZN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBzTy1SNW8tSjBhVk55dU9wRjNZN051UXhHOWRrSnBPcE8wajNYQ1JQV2FFRE1WbnRsZVF0UnNBcjRCYmgxM1l4QU4wS2U5X0ZjeG5ER2dwZW0yZw?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:04:00+00:00", "published_display": "19 Jun 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQdFRlQ1h2eDM0VHYwa253dVlmYmdfeFBnX2s2VkVtS3RLZU5NZVBsbWs5NDVLaVRFakFhTW91QUVTTU4zM2VYSjc0Q0Exc191TGZoM0xsVnlYaGZUTzZIR0hmZmFlUU1VdFdZejR5TXdoRklwVFlLZnlSeG9Xa1ZiT1pYekZKX2pnX011MzAzS0R2ekpVaW83empGb045NUFLU0E?oc=5", "source_name": "Market source", "published_at": "2026-06-18T22:15:04+00:00", "published_display": "18 Jun 2026 22:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slides Thursday, underperforms market", "summary": "AstraZeneca PLC (AZN) shares fell 2.36% on Thursday to \u00a3131.54, underperforming the broader market as the FTSE 100 Index declined by 1.04%. The company's stock closed 16.39% below its 52-week high, which was recorded on February 18th.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-falls-thursday-underperforms-market-b8f9b54e-dfd4e9a68018-af5798f21ec8?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T12:06:00", "published_display": "18 Jun 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca rallies Wednesday, outperforms market", "summary": "AstraZeneca PLC (AZN) shares rose 1.42% to \u00a3134.72 on Wednesday, outperforming the broader market as the FTSE 100 Index also saw gains. The pharmaceutical company's stock closed 14.37% below its 52-week high of \u00a3157.32, which was reached on February 18th.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-wednesday-outperforms-market-2846a8df-03297275c182-3addd2d99b15", "source_name": "MarketWatch", "published_at": "2026-06-17T12:07:00", "published_display": "17 Jun 2026 12:07", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics", "summary": "This Zacks Analyst Blog highlights research reports on five companies: Applied Materials Inc. (AMAT), GE Aerospace (GE), AstraZeneca PLC (AZN), Team, Inc. (TISI), and Applied Energetics Inc. (AERG). It details the financial performance and future outlook for each company, noting ", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-applied-073600895.html", "source_name": "Market source", "published_at": "2026-06-17T07:11:54", "published_display": "17 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan", "summary": "A AstraZeneca (AZN) officer, Mani Sharma, received 1 Ordinary Share as a compensation grant under the company\u2019s Share Incentive Plan. This award was valued at $179.75 per share, based on a GBP134.54 price and a GBP1.0000 to $1.3360 conversion rate. Following this transaction, Sha", "url": "https://www.stocktitan.net/sec-filings/AZN/form-4-astrazeneca-plc-insider-trading-activity-622beb5907a6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T03:09:29", "published_display": "17 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?", "summary": "AstraZeneca's stock has dropped 7.4% in the last three months, largely due to a pipeline setback involving its breast cancer drug candidate, camizestrant. Despite this, the company boasts a strong portfolio of 16 blockbuster drugs, significant growth in its oncology segment, and ", "url": "https://www.tradingview.com/news/zacks:289c9cd02094b:0-astrazeneca-stock-down-7-in-3-months-should-you-buy-sell-or-hold/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:29", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication", "summary": "AstraZeneca's Truqap (capivasertib) has received FDA approval for an expanded prostate cancer indication, making it the first AKT inhibitor approved in a second tumor type. The approval is for its use in combination with J&J\u2019s Zytiga and prednisone for PTEN-deficient mAPMN/S pros", "url": "https://finance.yahoo.com/sectors/healthcare/articles/astrazenecas-truqap-wins-fda-nod-125900625.html", "source_name": "Market source", "published_at": "2026-06-16T02:40:05", "published_display": "16 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EHA26: AstraZeneca battles Roche in untreated follicular lymphoma", "summary": "AstraZeneca presented preliminary safety data for its pipeline drug surovatamig at the 2026 European Hematological Association conference, aiming to provide a chemotherapy-free regimen for untreated advanced follicular lymphoma. This drug, acquired from TeneoTwo, is currently bei", "url": "https://www.clinicaltrialsarena.com/analyst-comment/eha26-astrazeneca-battles-roche-in-untreated-follicular-lymphoma/", "source_name": "Clinical Trials Arena", "published_at": "2026-06-16T02:40:05", "published_display": "16 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASTRAZENECA : Gets a Buy rating from Jefferies", "summary": "Jefferies has issued a \"Buy\" rating for AstraZeneca PLC, maintaining its target price at GBX 18000. This positive analyst recommendation suggests confidence in the pharmaceutical company's stock performance.", "url": "https://www.marketscreener.com/news/astrazeneca-gets-a-buy-rating-from-jefferies-ce7f5cdfd98af520", "source_name": "www.marketscreener.com", "published_at": "2026-06-16T01:21:00", "published_display": "16 Jun 2026 01:21", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca says AI is raising its odds where most drugs fail", "summary": "AstraZeneca CEO Pascal Soriot claims that artificial intelligence is improving the company's success rate in drug development, particularly at the costly Phase 3 trial stage where most drugs fail. Drug development is a notoriously expensive and high-risk endeavor, with only 10% o", "url": "https://www.thestreet.com/health/astrazeneca-says-ai-is-raising-its-odds-where-most-drugs-fail", "source_name": "TheStreet", "published_at": "2026-06-15T21:37:05", "published_display": "15 Jun 2026 21:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Aggressive Prostate Cancer Finally Has Targeted Treatment \u2014 AstraZeneca Wins FDA Nod", "summary": "AstraZeneca received FDA approval for Truqap, making it the first targeted treatment option for PTEN-deficient metastatic prostate cancer. This approval is supported by findings from the Phase III CAPItello-281 trial, showing a significant reduction in disease progression risk. A", "url": "https://www.benzinga.com/news/fda/26/06/53203946/this-aggressive-prostate-cancer-finally-has-targeted-treatment-astrazeneca-wins-fda-nod", "source_name": "Benzinga", "published_at": "2026-06-15T16:40:05", "published_display": "15 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slips Monday, underperforms market", "summary": "AstraZeneca PLC (AZN) shares fell by 1.95% on Monday, closing at \u00a3132.00, while the broader FTSE 100 Index also experienced a decline. This performance places AstraZeneca 16.09% below its 52-week high reached in February. The article highlights the company's underperformance in a", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-falls-monday-underperforms-market-c648c9f3-75ac1c3f690a-b0b93d34786f", "source_name": "MarketWatch", "published_at": "2026-06-15T12:07:00", "published_display": "15 Jun 2026 12:07", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer", "summary": "AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received US FDA approval for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive prostate cancer. This marks the first targeted therapy for this aggre", "url": "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-0bf135fcc7af.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:17", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer", "summary": "AstraZeneca's Truqap, combined with abiraterone and prednisone, has received US FDA approval as the first targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive prostate cancer. This approval is based on positive result", "url": "https://www.directorstalkinterviews.com/astrazeneca-plc-gains-us-approval-for-truqap-in-pten-deficient-prostate-cancer/4121253647", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T06:39:17", "published_display": "15 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE)", "summary": "AstraZeneca announced that the U.S. FDA has approved a label expansion for its anti-tumor agent Truqap (capivasertib). This approval allows Truqap to be used in a combination regimen for a specific type of prostate cancer. The medication will be available as a twice-daily pill.", "url": "https://seekingalpha.com/news/4603050-astrazeneca-truqap-ok-us-prostate-cancer", "source_name": "Seeking Alpha", "published_at": "2026-06-12T18:38:59", "published_display": "12 Jun 2026 18:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer", "summary": "AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received FDA approval in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive (mAPMN/S) prostate ca", "url": "https://www.marketscreener.com/news/astrazeneca-truqap-combination-approved-in-the-us-as-first-and-only-targeted-treatment-for-pten-de-ce7f5cd9dd88f22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-12T18:08:00", "published_display": "12 Jun 2026 18:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know", "summary": "Astrazeneca (AZN) saw a gain of 1.86% in its latest session, outperforming the S&P 500. Despite recent underperformance over the past month, analysts anticipate its upcoming earnings report to show $2.1 per share, with full fiscal year projections indicating growth. The company c", "url": "https://sg.finance.yahoo.com/news/astrazeneca-azn-outperforms-broader-market-221504654.html", "source_name": "Market source", "published_at": "2026-06-11T22:09:06", "published_display": "11 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations", "summary": "AstraZeneca is expected to rapidly advance its development of combination therapies for obesity and heart conditions. The company's strategy involves combining existing cardiovascular and renal drugs with new obesity treatments. This move is anticipated to be a major topic at the", "url": "https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-astrazeneca-to-move-fast-on-obesity-and-heart-pill-combinations-MVMM57BZ2BCEZOXGKBGYQNOHPQ/", "source_name": "Citeline News & Insights", "published_at": "2026-06-10T16:40:20", "published_display": "10 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials", "summary": "AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, is advancing to Phase 3 trials following strong results in two Phase 2b studies for weight loss and Type 2 diabetes. The VISTA trial showed an average weight reduction of 10.5% in obese or overweight participants, while the", "url": "https://www.benzinga.com/news/health-care/26/06/53092920/astrazenecas-glp-1-pill-heads-to-late-stage-trials", "source_name": "Benzinga", "published_at": "2026-06-09T16:10:47", "published_display": "09 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA", "summary": "AstraZeneca has announced positive Phase IIb trial results for elecoglipron, an oral GLP-1RA, showing significant weight loss in obesity patients and improved HbA1c levels in type 2 diabetes patients. These results pave the way for Phase III trials, positioning AstraZeneca to ent", "url": "https://www.clinicaltrialsarena.com/news/ada26-astrazeneca-unveils-positive-data-for-phase-iii-ready-oral-glp-1ra/", "source_name": "Clinical Trials Arena", "published_at": "2026-06-09T11:09:16", "published_display": "09 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi\u2011Year Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOa3VRV043YkI2dmVxQ1g2MDkyazR4b29RcmU3bHYzVDcwV2Y2SXBIVFhoZ1RERjJDUXFyQjJsTlAwemI5TFVDbHpWVXdMdGpYLWdjQndoV09aRExjang0TW9jaE53dmRCQzMwM29Ib2JGTTRhU3pjd2U2M0VsOWZZQnQwT3hNRlpVTXV0Z2pKWHBXUXhxMXNHSnRPWFBIUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca\u2019s cardiometabolic and kidney portfolio", "summary": "AstraZeneca's oral GLP-1 RA, elecoglipron, is advancing to a Phase III program following positive Phase IIb trial results for obesity and type 2 diabetes. In the VISTA trial, patients with obesity or overweight achieved significant weight loss and improved cardiometabolic risk fa", "url": "https://www.marketscreener.com/news/astrazeneca-elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme-and-unlock-ce7f5dd3da8df52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data", "summary": "AstraZeneca has announced the advancement of its oral GLP-1 receptor agonist, Elecoglipron, into Phase III clinical trials. This decision follows positive data from earlier trials, highlighting AstraZeneca's focus on cardiovascular, renal, and metabolism (CVRM) as a key growth ar", "url": "https://insights.citeline.com/scrip/conferences/ada-2026-astrazeneca-advances-oral-glp-1-elecoglipron-into-phase-iii-after-positive-trial-data-LGY6FPPK65CLDB6S4VT6VSLCFQ/", "source_name": "Citeline News & Insights", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca\u2019s oral GLP-1 advances to Phase III after strong trial results", "summary": "AstraZeneca's oral GLP-1 receptor agonist elecoglipron is moving to Phase III clinical trials following positive results from two mid-stage trials. The drug demonstrated significant weight loss and blood sugar reduction in adults with obesity/overweight and type 2 diabetes, respe", "url": "https://ng.investing.com/news/company-news/astrazenecas-oral-glp1-advances-to-phase-iii-after-strong-trial-results-2548536", "source_name": "Investing.com Nigeria", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca unveils data behind Phase III-bound oral GLP-1", "summary": "AstraZeneca has unveiled data supporting its Phase III-bound oral GLP-1 receptor agonist, danuglipron. The company is positioning danuglipron as a potential strong competitor in the rapidly growing obesity and diabetes market. This oral GLP-1 is expected to enter late-stage clini", "url": "https://firstwordpharma.com/story/7538725", "source_name": "FirstWord Pharma", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astra Obesity Pill Delivers 11.8% Weight Loss in Mid-Stage Trial", "summary": "AstraZeneca's experimental obesity pill, elecoglipron, demonstrated an 11.8% body weight loss in a mid-stage clinical trial. This positions AstraZeneca to enter the growing weight-loss drug market, though its pill showed less efficacy compared to rival drugs from Eli Lilly and No", "url": "https://www.bloomberg.com/news/articles/2026-06-08/astra-obesity-pill-delivers-11-8-weight-loss-in-mid-stage-trial", "source_name": "Bloomberg.com", "published_at": "2026-06-08T20:15:00", "published_display": "08 Jun 2026 20:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease", "summary": "AstraZeneca's Ultomiris (ravulizumab) has demonstrated a significant and early reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression, according to interim results from the Phase 3 I CAN trial. Patients treated with Ultomiris ex", "url": "https://www.benzinga.com/news/health-care/26/06/53066711/astrazeneca-reports-significant-proteinuria-reduction-with-ultomiris-in-rare-kidney-disease", "source_name": "Benzinga", "published_at": "2026-06-08T16:40:03", "published_display": "08 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca advances Friday, outperforms market", "summary": "AstraZeneca PLC (AZN) shares advanced 2.24% to \u00a3138.58 on Friday, outperforming the FTSE 100 Index. The increase occurred during a favorable trading session, with the FTSE 100 rising 0.07%. AstraZeneca's closing price was 11.91% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-friday-outperforms-market-df53f8b2-38fc88934e9e-8d62bd02b3cd?mod=marketwatch-automation", "source_name": "MarketWatch", "published_at": "2026-06-05T12:06:00", "published_display": "05 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca advances Thursday, outperforms market", "summary": "AstraZeneca PLC shares rose 2.60% to \u00a3135.54 on Thursday, outperforming the broader market as the FTSE 100 Index also saw a modest rise. The company's stock closed 13.84% below its 52-week high of \u00a3157.32, which was reached in February. This performance occurred on an overall pos", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-thursday-outperforms-market-a854c824-073ce6f69c41-683b6a1f9c70?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-04T12:06:00", "published_display": "04 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?", "summary": "AstraZeneca's oncology segment, contributing 44% of total product sales, is a primary growth driver, with strong demand for drugs like Tagrisso, Lynparza, and Enhertu. The company is strengthening its portfolio through label expansions and advancing a deep late-stage pipeline, in", "url": "https://www.tradingview.com/news/zacks:18f0992ea094b:0-can-astrazeneca-s-expanding-cancer-portfolio-sustain-momentum/", "source_name": "TradingView", "published_at": "2026-06-03T22:09:27", "published_display": "03 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions", "summary": "Deutsche Bank has reiterated its \"sell\" rating and 11,500p price target for AstraZeneca, despite positive data presented at the ASCO conference. The bank acknowledges AstraZeneca's strong oncology record but remains cautious due to unresolved questions regarding regulatory approv", "url": "https://www.proactiveinvestors.com.au/companies/news/1093366/leading-bank-maintains-sell-on-astrazeneca-at-11-500p-as-asco-glow-fails-to-resolve-key-pipeline-questions-1093366.html", "source_name": "Proactive financial news", "published_at": "2026-06-03T20:32:00", "published_display": "03 Jun 2026 20:32", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC Stock (AZN) Closed Down by 3.17% on Jun 1: Facts Behind the Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPVFg1VE5ObzZBRjF6RGoyVlBRTEozbE91OUI1NXlEWHg0eWR1X19rWjFqSUlnVERWTGVTOFR6YklPclJ5NEpzRVphQUZpdUpHS2libVRDYzEwN3FUZlFrd2JqeWgzMC1ac2hHNXJ5YXM2b1ZOZXJuMUhfakJGdXhYSTd2RWhTZjZjYnc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOdXp4alF1dXp4TXZULWFac2dCSi1MQm5IQUgwLUpIYlEzWVBFSHlUajR6WWRrQThncU1pVUNvSEo0NXZoYXBmT3I1TDdyQzJQbk1ZV2Z6X3hHQm02RFZpYmVBQjAzbXYzVFMxSUpyNUVxeE4zSFlaZGlqUTNCc0Q4S2VMNGliTVZBc0lVZmFoWDlBZDhYdFU1d1V0ei1sZHp1RTdJakk4OEMtaFNkNjA5TzhEWmRKNVRHRGdnSQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMXpjU2xJcWwxMHBuZUFtWl9xTjJINHlOWk51M1pDel92X0RpMGRMd3FhVmdnMGJfVGs1a3lWZG1QN01ZMW00WlV0QUJUd0RPSVRQMU1nNEZVLTJLYXJPQ2FMU3JyOWQ1VWJxUS03eDdrSVIzM2R0NE5pSGVnNENrQ0xZaGRKaUNWQnEwaGJTaw?oc=5", "source_name": "PharmTech.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At AstraZeneca (LSE:AZN) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNeHZ6UHg5WDVmaV9qaFNPaDNYeFlycnpOUGZwX1F3OFJtUnBGZkNfQ2RWY2Z6Ty1PeXNiUlNDSGZ3cEFwMGlKaHhySTUtdEI2cVhKVEc2YS1jV0NGMGQwZnBVLTg0cUNfa2hPS2pseDBoVERvcVQ0a1R3V2lFWjV0dU5FTFp1VzljYi11aWxYY25vNlRyb3RPbjBBQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOQnpjRDJxVHpwbFBzR0tkZmxtSlNaOE5IQnJTMTR2SGplM3JEVXNxM2FYb0M3ZThGSDdYaVc1bjlwTHEzR0xPcXo3MS0zc09MZkN3TUxwRU8ycEhHY28yQ2c5UUtJVm1jTHM5MWwtLU9USGFORzZ2ZEN2dmVEVzZ4UExKbm1EbVJSblRsb3huUXVaVWJaYXg1bGZJM0F2dU5TNVE?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AstraZeneca PLC (AZN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNX1hhOU1xaVRCYVNQNHlvd1Q1VmhpdjFybG9nUlIzai1ObmVuY3FVbmVWYUFOTkxQeW5yaTlXdkpPandQRXhHUXRNZnc0U2ZXYjN2NjFNbHA4QnhuSUZNYjJDOTFkTkp1TGs5bmNTakk5d2xWbFZWSHhuRjR5aUluTy1ST3BYNDlmeTVUd0pvRFRHSjlOUDlkRGprWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca shares dip after US regulatory panel rejects breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVGZEZVUzVE8wSlFUZnMzZ0ZMYUNBaFNWTjBEV3ZZWVM3NTBpdjBUNWJzbWlOdzVuNVFJaU8ydS04RmxDYXdzQ2JWaW5HVW5iQlRlLXY3ZHBQQ2syaXoxS0JRU0RTQm9uTThwbGlEcC1aRzJzdzRZWS1zMm5adXRzanh4UGY0MW91Y25rU1JxOXNXUTYyY2tNTGQ5SDNLOHZBaGpDS0g5bl9tQmlHUDFwbVFBX1U4STF2REp3ai13WTNmQjVfN0hNREtmMWxyWDlCazhkeFRVb1A3dXRnU1hpZzNnX0VvT3pv?oc=5", "source_name": "Reuters", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3FCZWNaMmxZQ0RzNVdQblRrMldOQkJlMEFGdVZSZVRENUEzTWdHSHJCN28xTGZFMl9tWC1NZkQtdkotbGl4Y2RQelAtekNXM2JKRzZrMklQM0hKSld3QUR5Qk51MDA5MzI4SE5JVktWM1dZRVdsTFd4dUpPTHBOcGZIeEVTdjVvbjd0ME92N2h5RlFnZGVpa3p6M09kcWlnSkxocA?oc=5", "source_name": "Reuters", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca stock falls after FDA panel votes against new cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNYWQ4cWdTbU1Bekl1LVhWZjMtSjZFY2N3OGk1YlRzaXZiUkI1TVlJNm85Uk9iY0N2WmFwQkZiVW9aTEc0ZHhhUkRQalhkZ3ViNWx5TWhQcjNyMVpIWWJpNWlOb1Y2dUJRQTBQOXFsaVVNc3ljVC15ZnZzZVlFTWxUMnh0VGpXQdIBiwFBVV95cUxOb2JzdjJacWh4bE9nalhqcDJtNlVpVW1SZ1p2djJoSWt5NG8ycjhLejZOVmZPR1JmejJ3RjF4eUNIQ2c3STRZNFRuNTBFTktPOFpRMEREY2ZmT3I5aVZTSW9jOXVpOUtlWmczTmVYc3ZVM0hoakYwOHpSRldjRXBOMFdlRHBINVpxMC1F?oc=5", "source_name": "CNBC", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNN2Nnc0hZMHM1V0o0QlpiTUZUTElrRDMxWFZ3SUttSk41Z01OWHFRV1dyY0ZTZGVrcEplSUJaNzdsWmQ0OTliY0MwZGxSNzg0MmVOZ3k4OU1OZXJJMEdhcWhZcmhRYl9TS2wwY3hZSkpIVERJdkJEWnhYZ2NTVU56V0x0UTV1Nm95YzE5NF84UGRtek1XNHF0VjE2dUJpUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMGc4UUxIS1RDMl9KVHQwT242SmdkX0U4TmRSeUgweGxNdTAzQ3U4MkdKVnNWY0lMX1RSd2g4WTZGU25ITDhGaXNTeVVJbWxJMDVNMDVuYi1PSE8yNUJ2dFBQNlNPMUZtODM5SWl0ck44ZGRCTG1pOGdGeERvN3lCZ1ljcjFsYWFYc2VSVDNjaW1vMzZEZFBYdDJwZVh1QzJQeERJT1g4MF93UzFPakxTSFJUOVN6UlBCSDNz?oc=5", "source_name": "TradingView", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca begins trading on the New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOdzZJRzllYkhyQmJkbnhFbGlwS2c0cmZFc3pzVTM3d2NfWVVheTAtbURpX2NDWUtReUpFT2tCTmU3NmhJcWExWjY0emZsY1dSQWJ0WnZJWjYzcktGZW9pLTViSnJRRUF4MVZBTFdZc0lhZlBiVmVhdWI5VXNHVlVtOFBra1Zmbmd1Sy1EWFhSMUpsRlVzRWZvUDk5aVNySmpIeW1BMnZucjltNnJGQm9QMXJNSnVfeFZHT09UU09wd0J4UDE4WnBiVU9n?oc=5", "source_name": "AstraZeneca", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNY2tsVjI2SUlpNU41M2JWeGt1bDJ4TnV0UTlTa1lSQzlsQTdFa1FTb3M5SjZ0RXFIbHFBMFRJdUhhX08tTkZXeFFQQmdrWEdMWTEzem5JV3dRNlphMjVKb1RxWmFNZmtucEEzRTFMaXJuZkJxNzdId0Voc1JObEVWV2FVcDdBTTM3MG9mM1pqYlpja0lfYmNKekJPVXVMQkhscFdpbA?oc=5", "source_name": "CNBC", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQY3QzY1NFN2NGUEJWNkdXcDlObHh4azVkY0YzRzBtZzItYWpiSmxqc1Y5RmxLYkVzbi1oWVhubHY5azRzYkpTVFRWY2I5SzluelBCMUtXdkJQVURUWDU0bFBTLWxwUkVlWG1obk5YSFBXTlF6YkNiRFhCRkNhcHhBeE55N1R0TWxhNUVmdkZ5WXR5dWU3YmpTUE93SFQ4RDV3TjQ3OGxfdDNHNXNrVWlCOWxn?oc=5", "source_name": "AstraZeneca", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to invest $2 billion as part of US manufacturing push", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNZ085MFo4Z1N6M2FGcXB2Qjg1Ni1oSU1kaXdSM1g4Zm9LeFBnUFM0QUhTLU51SWI2WjdGVzhaTUlSel9QWjVCbXU2NkJPWE0yb080WlgyMC1tcnMxVkpGaUp1WmhmaEU3NEtWNjRRdlFwenlaY1c4LXRmUGlzMUtKelQxdVBWQ2dGaXRCZEZSaWZ4eUNOVGRSS2ZZOWxLc1ZBVU5VdkVPMTFmSVNncmVnQVZzMVp0NlFjS3lhU2U1N2l6ekNYcHc?oc=5", "source_name": "Reuters", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca hits record high, cements lead as UK's biggest stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQcDcyR2lwOFpEanlHYU1GeXlkaWhDNFNjWjRzUG5oQldOc2NzdXYySFFDN1I4Wm4wanlzbk5MTFUteFFJZ3J5M1EyM0VSejhIeDBVc3Q1Uk52bmNDOFB5Q3ZacXFTZTNJWDJRdHFGNmF0cXotS2NKc1ZBNER0WXFDT18yZzJBQlo5V1dLQlJwMGh2SlBLVnZCcHNVVFZjUjRpTndOUTdvRElLZXBORjN0dk1CaHJKUU9qak95eF9qMlhBX3JSYzM2Vkxncw?oc=5", "source_name": "Reuters", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Stock Becomes UK\u2019s Biggest Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5nYVRlM2RkSVpIYklFdE1CcGZQbXRES3djZVA5NTFHZUpBVVRDSWoxaUF2X1VZZkpSRmtiUlhOQnY1UDl2UlN0WUxGY3hFbTU2VF83b2xEUklVYU1GS29iRDRDWFRPMjMtMXoxMnlENUFyOTFEV1ZOUzBIcmN0QQ?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQX09qUUF1Y3lEY0xCcWtmazZVRkFPb1hlNDVfdGJXTDZaaHczQy1qLWN4VTZVaWRTQk1PZlZjNU1laEhSSzZlUURsT203d0VQZHdwdnFDYmtfU3d1NWdrQ0trMklENHJCX2J6cHFuYmxuT244Umlwd1N5SlN2aWEyM0gxVHRHdHZ1Wjh6cGtjaG95blBFUVE?oc=5", "source_name": "Market source", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPOU9WVUc2Q09JY21laGlXRHBqSzg5Y2tPLTduZXNsRHJ1RGJPd2NDY2Jpb2dkNzJTWkFwYVNia0FSNVBUX3hTb052N2R0OUZMM0p6UGtlaGl3VEhoa1FjX1NEamx6ZWc0elE3dnAwUUR2VFY1VTRwWXZPZ3ROdkEtbDhWclZZdTVtNWdBWkEyLU1DYlhzX0ViS3h1cXJyTjlGbjhUYXYxWGxOTk51bHVBd0JMemZJNTdaSW94VWJoSGVvNURSc3NGSlRGMVRSMXZyQ0M1aFhmVQ?oc=5", "source_name": "Reuters", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's US listing may pull other firms from London in its wake", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOaXZWQVZYME1iS2JDSUV5bVVEdHJHZDZPWVFQWGtwcnk5a1FGM2lWY0dzZXVXeXUtNnUwYlIwd1ppMmpUeDJ5V0FOZUd2VEZScmNjM0Y5Wm5OY0RJYTNscnNpbTNVQzFtRTd0SHlxYkJaYmlFaF9SN0F4clFsUjJnZU44YnpqMnlnLVA0Sms1cEx0SXZpYlgybjNzSFhHOFAxMGxGNGJ6aU5kMjUzbE0wTTBzTDdGWFdJMGRSd1d0Y3Jla0FHc0FvdmdKUHBTaFhEdEdYR1BZRzQ?oc=5", "source_name": "Reuters", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca plots US stock listing amid industry pullback from Britain", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTWV5Zm9XX0lqZGZsZEhrUlR4OWx3TVA2akJsNHYtWjJrc0RWcnNqanNEMGZRNHdUTzlScFVNYUltVkxqODY3RFpZeW1VdjJqM2RNWXhucHY5MTM2azNsdlMzZ3ZHbXpEejhnem5ud2hRaFVydl9IdHhabm5qRE04cHZ2TmtlVi1HbG44TWpGWUxvU0FWeWppbk9yZlR4YzhqajBqQlVYZjQteFBNNWllTURYVUo3QQ?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca plans direct US stock listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LblAwekVXSmVWWkszRkNVU21CXzJEUGhUOVJGdnU3Ny1WMGpxMGlSTlBhcV8wY1ZoY1FMRmlDT1A3VWVGUVV3clo3WTh1NXhaaHFF?oc=5", "source_name": "FirstWord Pharma", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxOUm01dC1PRGdrMVR1YlhsX2ZHa0FNUTdRU2QzenJuOVdJVlBadHJCVmRfTEJEZFNuNWlSZFZrYzNFSVlCU2I4MkxHUWZ0bU5TS1BXNFhKbE1OUl9STllKTGRjd2VzZ2RUdjNxS3RtUmlZR3dsV3FEVEJqSU92RGQzMVJJSlZXckxoNzNMLWxwNWRxUVRTaE5wTTBrWHJPTDc0SWNQNjhaeGplelZGc3dudkY5WVJjejE3aUV2MnExZHBSQnBGXzZKWTVrSU5DYlByanUxVm1BVXl5VHZDa3dCVlYyUUVKQWdQNHVMd3JmWGh3X05Nc041aDFXU2pEVXBRNndOZ29IR29hX18yZ0xpUGdiWl9CNHJxWmc?oc=5", "source_name": "AstraZeneca", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today", "summary": "AstraZeneca (AZN) shares dipped 1.35% today, slightly underperforming the broader market due to a confluence of factors including ongoing concerns about its China subsidiary and recent analyst downgrades. Despite these short-term pressures and valuation scrutiny, the company main", "url": "https://www.kavout.com/market-lens/why-did-astrazeneca-azn-stock-dip-more-than-the-market-today", "source_name": "Kavout", "published_at": "2026-06-21T05:09:24", "published_display": "21 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNalVkSVBsa1oyTE1DU25VZjlQNWNrWkFTOFRFMEItWjFzaThNMk92WkRydTVCbnBhOFdCUGN0LU1TYUFyd0RfQml6eWdzM1YtV3BGdGZnQ1h6cHlMd1R2U2FtREI4dXhyTktUWW0xNmVXM1lWTzhlN2tleTN2UWktMmNXclE2SWFoT3NZVnh0emctblFYU2c?oc=5", "source_name": "Market source", "published_at": "2026-06-20T02:07:00+00:00", "published_display": "20 Jun 2026 02:07", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Takes Oral GLP 1 Drug Elecoglipron Into Phase III", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-takes-oral-170935835.html", "source_name": "Simply Wall St.", "published_at": "2026-06-19T17:09:35+00:00", "published_display": "19 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T16:33:51+00:00", "published_display": "19 Jun 2026 16:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOYzJ1VmltcFhibVVwU0stc19wdXd3Z0tKdU1wTUFrcjEzeTI2RnhHc3gxX3YybVZJSVBhQmVreldvLU9SeHVmLTNTTjU0WlpZSDA0aWtzWFhzWW1RS01VYzJTUE5DUDM4RGFtZWFrcWQ1NnFWakZuZUw0VTA4WWFxRWg1X3l0Y2hDZEQ1ZzZNNkFFT1R2ZlYyLVFwUHk?oc=5", "source_name": "Market source", "published_at": "2026-06-19T13:09:58+00:00", "published_display": "19 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AZN News | ASTRAZENECA PLC (NYSE:AZN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBzTy1SNW8tSjBhVk55dU9wRjNZN051UXhHOWRrSnBPcE8wajNYQ1JQV2FFRE1WbnRsZVF0UnNBcjRCYmgxM1l4QU4wS2U5X0ZjeG5ER2dwZW0yZw?oc=5", "source_name": "ChartMill", "published_at": "2026-06-19T00:04:00+00:00", "published_display": "19 Jun 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQdFRlQ1h2eDM0VHYwa253dVlmYmdfeFBnX2s2VkVtS3RLZU5NZVBsbWs5NDVLaVRFakFhTW91QUVTTU4zM2VYSjc0Q0Exc191TGZoM0xsVnlYaGZUTzZIR0hmZmFlUU1VdFdZejR5TXdoRklwVFlLZnlSeG9Xa1ZiT1pYekZKX2pnX011MzAzS0R2ekpVaW83empGb045NUFLU0E?oc=5", "source_name": "Market source", "published_at": "2026-06-18T22:15:04+00:00", "published_display": "18 Jun 2026 22:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slides Thursday, underperforms market", "summary": "AstraZeneca PLC (AZN) shares fell 2.36% on Thursday to \u00a3131.54, underperforming the broader market as the FTSE 100 Index declined by 1.04%. The company's stock closed 16.39% below its 52-week high, which was recorded on February 18th.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-falls-thursday-underperforms-market-b8f9b54e-dfd4e9a68018-af5798f21ec8?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-18T12:06:00", "published_display": "18 Jun 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca rallies Wednesday, outperforms market", "summary": "AstraZeneca PLC (AZN) shares rose 1.42% to \u00a3134.72 on Wednesday, outperforming the broader market as the FTSE 100 Index also saw gains. The pharmaceutical company's stock closed 14.37% below its 52-week high of \u00a3157.32, which was reached on February 18th.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-wednesday-outperforms-market-2846a8df-03297275c182-3addd2d99b15", "source_name": "MarketWatch", "published_at": "2026-06-17T12:07:00", "published_display": "17 Jun 2026 12:07", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics", "summary": "This Zacks Analyst Blog highlights research reports on five companies: Applied Materials Inc. (AMAT), GE Aerospace (GE), AstraZeneca PLC (AZN), Team, Inc. (TISI), and Applied Energetics Inc. (AERG). It details the financial performance and future outlook for each company, noting ", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-applied-073600895.html", "source_name": "Market source", "published_at": "2026-06-17T07:11:54", "published_display": "17 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan", "summary": "A AstraZeneca (AZN) officer, Mani Sharma, received 1 Ordinary Share as a compensation grant under the company\u2019s Share Incentive Plan. This award was valued at $179.75 per share, based on a GBP134.54 price and a GBP1.0000 to $1.3360 conversion rate. Following this transaction, Sha", "url": "https://www.stocktitan.net/sec-filings/AZN/form-4-astrazeneca-plc-insider-trading-activity-622beb5907a6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T03:09:29", "published_display": "17 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?", "summary": "AstraZeneca's stock has dropped 7.4% in the last three months, largely due to a pipeline setback involving its breast cancer drug candidate, camizestrant. Despite this, the company boasts a strong portfolio of 16 blockbuster drugs, significant growth in its oncology segment, and ", "url": "https://www.tradingview.com/news/zacks:289c9cd02094b:0-astrazeneca-stock-down-7-in-3-months-should-you-buy-sell-or-hold/", "source_name": "TradingView", "published_at": "2026-06-16T14:09:29", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication", "summary": "AstraZeneca's Truqap (capivasertib) has received FDA approval for an expanded prostate cancer indication, making it the first AKT inhibitor approved in a second tumor type. The approval is for its use in combination with J&J\u2019s Zytiga and prednisone for PTEN-deficient mAPMN/S pros", "url": "https://finance.yahoo.com/sectors/healthcare/articles/astrazenecas-truqap-wins-fda-nod-125900625.html", "source_name": "Market source", "published_at": "2026-06-16T02:40:05", "published_display": "16 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EHA26: AstraZeneca battles Roche in untreated follicular lymphoma", "summary": "AstraZeneca presented preliminary safety data for its pipeline drug surovatamig at the 2026 European Hematological Association conference, aiming to provide a chemotherapy-free regimen for untreated advanced follicular lymphoma. This drug, acquired from TeneoTwo, is currently bei", "url": "https://www.clinicaltrialsarena.com/analyst-comment/eha26-astrazeneca-battles-roche-in-untreated-follicular-lymphoma/", "source_name": "Clinical Trials Arena", "published_at": "2026-06-16T02:40:05", "published_display": "16 Jun 2026 02:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASTRAZENECA : Gets a Buy rating from Jefferies", "summary": "Jefferies has issued a \"Buy\" rating for AstraZeneca PLC, maintaining its target price at GBX 18000. This positive analyst recommendation suggests confidence in the pharmaceutical company's stock performance.", "url": "https://www.marketscreener.com/news/astrazeneca-gets-a-buy-rating-from-jefferies-ce7f5cdfd98af520", "source_name": "www.marketscreener.com", "published_at": "2026-06-16T01:21:00", "published_display": "16 Jun 2026 01:21", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca says AI is raising its odds where most drugs fail", "summary": "AstraZeneca CEO Pascal Soriot claims that artificial intelligence is improving the company's success rate in drug development, particularly at the costly Phase 3 trial stage where most drugs fail. Drug development is a notoriously expensive and high-risk endeavor, with only 10% o", "url": "https://www.thestreet.com/health/astrazeneca-says-ai-is-raising-its-odds-where-most-drugs-fail", "source_name": "TheStreet", "published_at": "2026-06-15T21:37:05", "published_display": "15 Jun 2026 21:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Aggressive Prostate Cancer Finally Has Targeted Treatment \u2014 AstraZeneca Wins FDA Nod", "summary": "AstraZeneca received FDA approval for Truqap, making it the first targeted treatment option for PTEN-deficient metastatic prostate cancer. This approval is supported by findings from the Phase III CAPItello-281 trial, showing a significant reduction in disease progression risk. A", "url": "https://www.benzinga.com/news/fda/26/06/53203946/this-aggressive-prostate-cancer-finally-has-targeted-treatment-astrazeneca-wins-fda-nod", "source_name": "Benzinga", "published_at": "2026-06-15T16:40:05", "published_display": "15 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slips Monday, underperforms market", "summary": "AstraZeneca PLC (AZN) shares fell by 1.95% on Monday, closing at \u00a3132.00, while the broader FTSE 100 Index also experienced a decline. This performance places AstraZeneca 16.09% below its 52-week high reached in February. The article highlights the company's underperformance in a", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-falls-monday-underperforms-market-c648c9f3-75ac1c3f690a-b0b93d34786f", "source_name": "MarketWatch", "published_at": "2026-06-15T12:07:00", "published_display": "15 Jun 2026 12:07", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer", "summary": "AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received US FDA approval for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive prostate cancer. This marks the first targeted therapy for this aggre", "url": "https://www.stocktitan.net/sec-filings/AZN/6-k-astrazeneca-plc-current-report-foreign-issuer-0bf135fcc7af.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:17", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer", "summary": "AstraZeneca's Truqap, combined with abiraterone and prednisone, has received US FDA approval as the first targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive prostate cancer. This approval is based on positive result", "url": "https://www.directorstalkinterviews.com/astrazeneca-plc-gains-us-approval-for-truqap-in-pten-deficient-prostate-cancer/4121253647", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T06:39:17", "published_display": "15 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE)", "summary": "AstraZeneca announced that the U.S. FDA has approved a label expansion for its anti-tumor agent Truqap (capivasertib). This approval allows Truqap to be used in a combination regimen for a specific type of prostate cancer. The medication will be available as a twice-daily pill.", "url": "https://seekingalpha.com/news/4603050-astrazeneca-truqap-ok-us-prostate-cancer", "source_name": "Seeking Alpha", "published_at": "2026-06-12T18:38:59", "published_display": "12 Jun 2026 18:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer", "summary": "AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has received FDA approval in the US as the first and only targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-na\u00efve or sensitive (mAPMN/S) prostate ca", "url": "https://www.marketscreener.com/news/astrazeneca-truqap-combination-approved-in-the-us-as-first-and-only-targeted-treatment-for-pten-de-ce7f5cd9dd88f22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-12T18:08:00", "published_display": "12 Jun 2026 18:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know", "summary": "Astrazeneca (AZN) saw a gain of 1.86% in its latest session, outperforming the S&P 500. Despite recent underperformance over the past month, analysts anticipate its upcoming earnings report to show $2.1 per share, with full fiscal year projections indicating growth. The company c", "url": "https://sg.finance.yahoo.com/news/astrazeneca-azn-outperforms-broader-market-221504654.html", "source_name": "Market source", "published_at": "2026-06-11T22:09:06", "published_display": "11 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations", "summary": "AstraZeneca is expected to rapidly advance its development of combination therapies for obesity and heart conditions. The company's strategy involves combining existing cardiovascular and renal drugs with new obesity treatments. This move is anticipated to be a major topic at the", "url": "https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/ada-2026-astrazeneca-to-move-fast-on-obesity-and-heart-pill-combinations-MVMM57BZ2BCEZOXGKBGYQNOHPQ/", "source_name": "Citeline News & Insights", "published_at": "2026-06-10T16:40:20", "published_display": "10 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials", "summary": "AstraZeneca's oral GLP-1 receptor agonist, elecoglipron, is advancing to Phase 3 trials following strong results in two Phase 2b studies for weight loss and Type 2 diabetes. The VISTA trial showed an average weight reduction of 10.5% in obese or overweight participants, while the", "url": "https://www.benzinga.com/news/health-care/26/06/53092920/astrazenecas-glp-1-pill-heads-to-late-stage-trials", "source_name": "Benzinga", "published_at": "2026-06-09T16:10:47", "published_display": "09 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA", "summary": "AstraZeneca has announced positive Phase IIb trial results for elecoglipron, an oral GLP-1RA, showing significant weight loss in obesity patients and improved HbA1c levels in type 2 diabetes patients. These results pave the way for Phase III trials, positioning AstraZeneca to ent", "url": "https://www.clinicaltrialsarena.com/news/ada26-astrazeneca-unveils-positive-data-for-phase-iii-ready-oral-glp-1ra/", "source_name": "Clinical Trials Arena", "published_at": "2026-06-09T11:09:16", "published_display": "09 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi\u2011Year Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOa3VRV043YkI2dmVxQ1g2MDkyazR4b29RcmU3bHYzVDcwV2Y2SXBIVFhoZ1RERjJDUXFyQjJsTlAwemI5TFVDbHpWVXdMdGpYLWdjQndoV09aRExjang0TW9jaE53dmRCQzMwM29Ib2JGTTRhU3pjd2U2M0VsOWZZQnQwT3hNRlpVTXV0Z2pKWHBXUXhxMXNHSnRPWFBIUQ?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca\u2019s cardiometabolic and kidney portfolio", "summary": "AstraZeneca's oral GLP-1 RA, elecoglipron, is advancing to a Phase III program following positive Phase IIb trial results for obesity and type 2 diabetes. In the VISTA trial, patients with obesity or overweight achieved significant weight loss and improved cardiometabolic risk fa", "url": "https://www.marketscreener.com/news/astrazeneca-elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme-and-unlock-ce7f5dd3da8df52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data", "summary": "AstraZeneca has announced the advancement of its oral GLP-1 receptor agonist, Elecoglipron, into Phase III clinical trials. This decision follows positive data from earlier trials, highlighting AstraZeneca's focus on cardiovascular, renal, and metabolism (CVRM) as a key growth ar", "url": "https://insights.citeline.com/scrip/conferences/ada-2026-astrazeneca-advances-oral-glp-1-elecoglipron-into-phase-iii-after-positive-trial-data-LGY6FPPK65CLDB6S4VT6VSLCFQ/", "source_name": "Citeline News & Insights", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca\u2019s oral GLP-1 advances to Phase III after strong trial results", "summary": "AstraZeneca's oral GLP-1 receptor agonist elecoglipron is moving to Phase III clinical trials following positive results from two mid-stage trials. The drug demonstrated significant weight loss and blood sugar reduction in adults with obesity/overweight and type 2 diabetes, respe", "url": "https://ng.investing.com/news/company-news/astrazenecas-oral-glp1-advances-to-phase-iii-after-strong-trial-results-2548536", "source_name": "Investing.com Nigeria", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca unveils data behind Phase III-bound oral GLP-1", "summary": "AstraZeneca has unveiled data supporting its Phase III-bound oral GLP-1 receptor agonist, danuglipron. The company is positioning danuglipron as a potential strong competitor in the rapidly growing obesity and diabetes market. This oral GLP-1 is expected to enter late-stage clini", "url": "https://firstwordpharma.com/story/7538725", "source_name": "FirstWord Pharma", "published_at": "2026-06-08T20:40:03", "published_display": "08 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astra Obesity Pill Delivers 11.8% Weight Loss in Mid-Stage Trial", "summary": "AstraZeneca's experimental obesity pill, elecoglipron, demonstrated an 11.8% body weight loss in a mid-stage clinical trial. This positions AstraZeneca to enter the growing weight-loss drug market, though its pill showed less efficacy compared to rival drugs from Eli Lilly and No", "url": "https://www.bloomberg.com/news/articles/2026-06-08/astra-obesity-pill-delivers-11-8-weight-loss-in-mid-stage-trial", "source_name": "Bloomberg.com", "published_at": "2026-06-08T20:15:00", "published_display": "08 Jun 2026 20:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease", "summary": "AstraZeneca's Ultomiris (ravulizumab) has demonstrated a significant and early reduction in proteinuria in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression, according to interim results from the Phase 3 I CAN trial. Patients treated with Ultomiris ex", "url": "https://www.benzinga.com/news/health-care/26/06/53066711/astrazeneca-reports-significant-proteinuria-reduction-with-ultomiris-in-rare-kidney-disease", "source_name": "Benzinga", "published_at": "2026-06-08T16:40:03", "published_display": "08 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca advances Friday, outperforms market", "summary": "AstraZeneca PLC (AZN) shares advanced 2.24% to \u00a3138.58 on Friday, outperforming the FTSE 100 Index. The increase occurred during a favorable trading session, with the FTSE 100 rising 0.07%. AstraZeneca's closing price was 11.91% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-friday-outperforms-market-df53f8b2-38fc88934e9e-8d62bd02b3cd?mod=marketwatch-automation", "source_name": "MarketWatch", "published_at": "2026-06-05T12:06:00", "published_display": "05 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca advances Thursday, outperforms market", "summary": "AstraZeneca PLC shares rose 2.60% to \u00a3135.54 on Thursday, outperforming the broader market as the FTSE 100 Index also saw a modest rise. The company's stock closed 13.84% below its 52-week high of \u00a3157.32, which was reached in February. This performance occurred on an overall pos", "url": "https://www.marketwatch.com/data-news/astrazeneca-plc-stock-rises-thursday-outperforms-market-a854c824-073ce6f69c41-683b6a1f9c70?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-06-04T12:06:00", "published_display": "04 Jun 2026 12:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?", "summary": "AstraZeneca's oncology segment, contributing 44% of total product sales, is a primary growth driver, with strong demand for drugs like Tagrisso, Lynparza, and Enhertu. The company is strengthening its portfolio through label expansions and advancing a deep late-stage pipeline, in", "url": "https://www.tradingview.com/news/zacks:18f0992ea094b:0-can-astrazeneca-s-expanding-cancer-portfolio-sustain-momentum/", "source_name": "TradingView", "published_at": "2026-06-03T22:09:27", "published_display": "03 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions", "summary": "Deutsche Bank has reiterated its \"sell\" rating and 11,500p price target for AstraZeneca, despite positive data presented at the ASCO conference. The bank acknowledges AstraZeneca's strong oncology record but remains cautious due to unresolved questions regarding regulatory approv", "url": "https://www.proactiveinvestors.com.au/companies/news/1093366/leading-bank-maintains-sell-on-astrazeneca-at-11-500p-as-asco-glow-fails-to-resolve-key-pipeline-questions-1093366.html", "source_name": "Proactive financial news", "published_at": "2026-06-03T20:32:00", "published_display": "03 Jun 2026 20:32", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC Stock (AZN) Closed Down by 3.17% on Jun 1: Facts Behind the Movement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPVFg1VE5ObzZBRjF6RGoyVlBRTEozbE91OUI1NXlEWHg0eWR1X19rWjFqSUlnVERWTGVTOFR6YklPclJ5NEpzRVphQUZpdUpHS2libVRDYzEwN3FUZlFrd2JqeWgzMC1ac2hHNXJ5YXM2b1ZOZXJuMUhfakJGdXhYSTd2RWhTZjZjYnc?oc=5", "source_name": "TradingKey", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOdXp4alF1dXp4TXZULWFac2dCSi1MQm5IQUgwLUpIYlEzWVBFSHlUajR6WWRrQThncU1pVUNvSEo0NXZoYXBmT3I1TDdyQzJQbk1ZV2Z6X3hHQm02RFZpYmVBQjAzbXYzVFMxSUpyNUVxeE4zSFlaZGlqUTNCc0Q4S2VMNGliTVZBc0lVZmFoWDlBZDhYdFU1d1V0ei1sZHp1RTdJakk4OEMtaFNkNjA5TzhEWmRKNVRHRGdnSQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMXpjU2xJcWwxMHBuZUFtWl9xTjJINHlOWk51M1pDel92X0RpMGRMd3FhVmdnMGJfVGs1a3lWZG1QN01ZMW00WlV0QUJUd0RPSVRQMU1nNEZVLTJLYXJPQ2FMU3JyOWQ1VWJxUS03eDdrSVIzM2R0NE5pSGVnNENrQ0xZaGRKaUNWQnEwaGJTaw?oc=5", "source_name": "PharmTech.com", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Fresh Look At AstraZeneca (LSE:AZN) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNeHZ6UHg5WDVmaV9qaFNPaDNYeFlycnpOUGZwX1F3OFJtUnBGZkNfQ2RWY2Z6Ty1PeXNiUlNDSGZ3cEFwMGlKaHhySTUtdEI2cVhKVEc2YS1jV0NGMGQwZnBVLTg0cUNfa2hPS2pseDBoVERvcVQ0a1R3V2lFWjV0dU5FTFp1VzljYi11aWxYY25vNlRyb3RPbjBBQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca PLC (AZN) Stock Falls as FDA Panel Votes Against New Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOQnpjRDJxVHpwbFBzR0tkZmxtSlNaOE5IQnJTMTR2SGplM3JEVXNxM2FYb0M3ZThGSDdYaVc1bjlwTHEzR0xPcXo3MS0zc09MZkN3TUxwRU8ycEhHY28yQ2c5UUtJVm1jTHM5MWwtLU9USGFORzZ2ZEN2dmVEVzZ4UExKbm1EbVJSblRsb3huUXVaVWJaYXg1bGZJM0F2dU5TNVE?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is AstraZeneca PLC (AZN) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNX1hhOU1xaVRCYVNQNHlvd1Q1VmhpdjFybG9nUlIzai1ObmVuY3FVbmVWYUFOTkxQeW5yaTlXdkpPandQRXhHUXRNZnc0U2ZXYjN2NjFNbHA4QnhuSUZNYjJDOTFkTkp1TGs5bmNTakk5d2xWbFZWSHhuRjR5aUluTy1ST3BYNDlmeTVUd0pvRFRHSjlOUDlkRGprWQ?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca shares dip after US regulatory panel rejects breast cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPVGZEZVUzVE8wSlFUZnMzZ0ZMYUNBaFNWTjBEV3ZZWVM3NTBpdjBUNWJzbWlOdzVuNVFJaU8ydS04RmxDYXdzQ2JWaW5HVW5iQlRlLXY3ZHBQQ2syaXoxS0JRU0RTQm9uTThwbGlEcC1aRzJzdzRZWS1zMm5adXRzanh4UGY0MW91Y25rU1JxOXNXUTYyY2tNTGQ5SDNLOHZBaGpDS0g5bl9tQmlHUDFwbVFBX1U4STF2REp3ai13WTNmQjVfN0hNREtmMWxyWDlCazhkeFRVb1A3dXRnU1hpZzNnX0VvT3pv?oc=5", "source_name": "Reuters", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3FCZWNaMmxZQ0RzNVdQblRrMldOQkJlMEFGdVZSZVRENUEzTWdHSHJCN28xTGZFMl9tWC1NZkQtdkotbGl4Y2RQelAtekNXM2JKRzZrMklQM0hKSld3QUR5Qk51MDA5MzI4SE5JVktWM1dZRVdsTFd4dUpPTHBOcGZIeEVTdjVvbjd0ME92N2h5RlFnZGVpa3p6M09kcWlnSkxocA?oc=5", "source_name": "Reuters", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca stock falls after FDA panel votes against new cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNYWQ4cWdTbU1Bekl1LVhWZjMtSjZFY2N3OGk1YlRzaXZiUkI1TVlJNm85Uk9iY0N2WmFwQkZiVW9aTEc0ZHhhUkRQalhkZ3ViNWx5TWhQcjNyMVpIWWJpNWlOb1Y2dUJRQTBQOXFsaVVNc3ljVC15ZnZzZVlFTWxUMnh0VGpXQdIBiwFBVV95cUxOb2JzdjJacWh4bE9nalhqcDJtNlVpVW1SZ1p2djJoSWt5NG8ycjhLejZOVmZPR1JmejJ3RjF4eUNIQ2c3STRZNFRuNTBFTktPOFpRMEREY2ZmT3I5aVZTSW9jOXVpOUtlWmczTmVYc3ZVM0hoakYwOHpSRldjRXBOMFdlRHBINVpxMC1F?oc=5", "source_name": "CNBC", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNN2Nnc0hZMHM1V0o0QlpiTUZUTElrRDMxWFZ3SUttSk41Z01OWHFRV1dyY0ZTZGVrcEplSUJaNzdsWmQ0OTliY0MwZGxSNzg0MmVOZ3k4OU1OZXJJMEdhcWhZcmhRYl9TS2wwY3hZSkpIVERJdkJEWnhYZ2NTVU56V0x0UTV1Nm95YzE5NF84UGRtek1XNHF0VjE2dUJpUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMGc4UUxIS1RDMl9KVHQwT242SmdkX0U4TmRSeUgweGxNdTAzQ3U4MkdKVnNWY0lMX1RSd2g4WTZGU25ITDhGaXNTeVVJbWxJMDVNMDVuYi1PSE8yNUJ2dFBQNlNPMUZtODM5SWl0ck44ZGRCTG1pOGdGeERvN3lCZ1ljcjFsYWFYc2VSVDNjaW1vMzZEZFBYdDJwZVh1QzJQeERJT1g4MF93UzFPakxTSFJUOVN6UlBCSDNz?oc=5", "source_name": "TradingView", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca begins trading on the New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOdzZJRzllYkhyQmJkbnhFbGlwS2c0cmZFc3pzVTM3d2NfWVVheTAtbURpX2NDWUtReUpFT2tCTmU3NmhJcWExWjY0emZsY1dSQWJ0WnZJWjYzcktGZW9pLTViSnJRRUF4MVZBTFdZc0lhZlBiVmVhdWI5VXNHVlVtOFBra1Zmbmd1Sy1EWFhSMUpsRlVzRWZvUDk5aVNySmpIeW1BMnZucjltNnJGQm9QMXJNSnVfeFZHT09UU09wd0J4UDE4WnBiVU9n?oc=5", "source_name": "AstraZeneca", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNY2tsVjI2SUlpNU41M2JWeGt1bDJ4TnV0UTlTa1lSQzlsQTdFa1FTb3M5SjZ0RXFIbHFBMFRJdUhhX08tTkZXeFFQQmdrWEdMWTEzem5JV3dRNlphMjVKb1RxWmFNZmtucEEzRTFMaXJuZkJxNzdId0Voc1JObEVWV2FVcDdBTTM3MG9mM1pqYlpja0lfYmNKekJPVXVMQkhscFdpbA?oc=5", "source_name": "CNBC", "published_at": "2026-02-01T08:00:00+00:00", "published_display": "01 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQY3QzY1NFN2NGUEJWNkdXcDlObHh4azVkY0YzRzBtZzItYWpiSmxqc1Y5RmxLYkVzbi1oWVhubHY5azRzYkpTVFRWY2I5SzluelBCMUtXdkJQVURUWDU0bFBTLWxwUkVlWG1obk5YSFBXTlF6YkNiRFhCRkNhcHhBeE55N1R0TWxhNUVmdkZ5WXR5dWU3YmpTUE93SFQ4RDV3TjQ3OGxfdDNHNXNrVWlCOWxn?oc=5", "source_name": "AstraZeneca", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to invest $2 billion as part of US manufacturing push", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNZ085MFo4Z1N6M2FGcXB2Qjg1Ni1oSU1kaXdSM1g4Zm9LeFBnUFM0QUhTLU51SWI2WjdGVzhaTUlSel9QWjVCbXU2NkJPWE0yb080WlgyMC1tcnMxVkpGaUp1WmhmaEU3NEtWNjRRdlFwenlaY1c4LXRmUGlzMUtKelQxdVBWQ2dGaXRCZEZSaWZ4eUNOVGRSS2ZZOWxLc1ZBVU5VdkVPMTFmSVNncmVnQVZzMVp0NlFjS3lhU2U1N2l6ekNYcHc?oc=5", "source_name": "Reuters", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca hits record high, cements lead as UK's biggest stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQcDcyR2lwOFpEanlHYU1GeXlkaWhDNFNjWjRzUG5oQldOc2NzdXYySFFDN1I4Wm4wanlzbk5MTFUteFFJZ3J5M1EyM0VSejhIeDBVc3Q1Uk52bmNDOFB5Q3ZacXFTZTNJWDJRdHFGNmF0cXotS2NKc1ZBNER0WXFDT18yZzJBQlo5V1dLQlJwMGh2SlBLVnZCcHNVVFZjUjRpTndOUTdvRElLZXBORjN0dk1CaHJKUU9qak95eF9qMlhBX3JSYzM2Vkxncw?oc=5", "source_name": "Reuters", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Stock Becomes UK\u2019s Biggest Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5nYVRlM2RkSVpIYklFdE1CcGZQbXRES3djZVA5NTFHZUpBVVRDSWoxaUF2X1VZZkpSRmtiUlhOQnY1UDl2UlN0WUxGY3hFbTU2VF83b2xEUklVYU1GS29iRDRDWFRPMjMtMXoxMnlENUFyOTFEV1ZOUzBIcmN0QQ?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQX09qUUF1Y3lEY0xCcWtmazZVRkFPb1hlNDVfdGJXTDZaaHczQy1qLWN4VTZVaWRTQk1PZlZjNU1laEhSSzZlUURsT203d0VQZHdwdnFDYmtfU3d1NWdrQ0trMklENHJCX2J6cHFuYmxuT244Umlwd1N5SlN2aWEyM0gxVHRHdHZ1Wjh6cGtjaG95blBFUVE?oc=5", "source_name": "Market source", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPOU9WVUc2Q09JY21laGlXRHBqSzg5Y2tPLTduZXNsRHJ1RGJPd2NDY2Jpb2dkNzJTWkFwYVNia0FSNVBUX3hTb052N2R0OUZMM0p6UGtlaGl3VEhoa1FjX1NEamx6ZWc0elE3dnAwUUR2VFY1VTRwWXZPZ3ROdkEtbDhWclZZdTVtNWdBWkEyLU1DYlhzX0ViS3h1cXJyTjlGbjhUYXYxWGxOTk51bHVBd0JMemZJNTdaSW94VWJoSGVvNURSc3NGSlRGMVRSMXZyQ0M1aFhmVQ?oc=5", "source_name": "Reuters", "published_at": "2025-10-13T07:00:00+00:00", "published_display": "13 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca's US listing may pull other firms from London in its wake", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOaXZWQVZYME1iS2JDSUV5bVVEdHJHZDZPWVFQWGtwcnk5a1FGM2lWY0dzZXVXeXUtNnUwYlIwd1ppMmpUeDJ5V0FOZUd2VEZScmNjM0Y5Wm5OY0RJYTNscnNpbTNVQzFtRTd0SHlxYkJaYmlFaF9SN0F4clFsUjJnZU44YnpqMnlnLVA0Sms1cEx0SXZpYlgybjNzSFhHOFAxMGxGNGJ6aU5kMjUzbE0wTTBzTDdGWFdJMGRSd1d0Y3Jla0FHc0FvdmdKUHBTaFhEdEdYR1BZRzQ?oc=5", "source_name": "Reuters", "published_at": "2025-10-02T07:00:00+00:00", "published_display": "02 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca plots US stock listing amid industry pullback from Britain", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOTWV5Zm9XX0lqZGZsZEhrUlR4OWx3TVA2akJsNHYtWjJrc0RWcnNqanNEMGZRNHdUTzlScFVNYUltVkxqODY3RFpZeW1VdjJqM2RNWXhucHY5MTM2azNsdlMzZ3ZHbXpEejhnem5ud2hRaFVydl9IdHhabm5qRE04cHZ2TmtlVi1HbG44TWpGWUxvU0FWeWppbk9yZlR4YzhqajBqQlVYZjQteFBNNWllTURYVUo3QQ?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca plans direct US stock listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LblAwekVXSmVWWkszRkNVU21CXzJEUGhUOVJGdnU3Ny1WMGpxMGlSTlBhcV8wY1ZoY1FMRmlDT1A3VWVGUVV3clo3WTh1NXhaaHFF?oc=5", "source_name": "FirstWord Pharma", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxOUm01dC1PRGdrMVR1YlhsX2ZHa0FNUTdRU2QzenJuOVdJVlBadHJCVmRfTEJEZFNuNWlSZFZrYzNFSVlCU2I4MkxHUWZ0bU5TS1BXNFhKbE1OUl9STllKTGRjd2VzZ2RUdjNxS3RtUmlZR3dsV3FEVEJqSU92RGQzMVJJSlZXckxoNzNMLWxwNWRxUVRTaE5wTTBrWHJPTDc0SWNQNjhaeGplelZGc3dudkY5WVJjejE3aUV2MnExZHBSQnBGXzZKWTVrSU5DYlByanUxVm1BVXl5VHZDa3dCVlYyUUVKQWdQNHVMd3JmWGh3X05Nc041aDFXU2pEVXBRNndOZ29IR29hX18yZ0xpUGdiWl9CNHJxWmc?oc=5", "source_name": "AstraZeneca", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 111, "total_relevant": 61, "sentiment_summary": {"positive": 27, "negative": 7, "neutral": 27, "score": 58, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 26.55, "count": 40}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.55, "count": 7}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.9, "count": 1}], "positive_events": 27, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 174.93, "latest_week": "2026-06-19", "one_week_move": -2.1, "four_week_move": -6.5, "twelve_week_move": -7.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.257098, "market_dynamics_buy_signal": false, "relative_strength": -9.075935, "fair_value_gap": 18.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 55.5007, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.1% over one week, -6.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Reuters", "count": 6}, {"label": "MarketWatch", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Benzinga", "count": 3}, {"label": "AstraZeneca", "count": 3}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 61}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Regulatory and legal", "count": 7}, {"label": "Earnings", "count": 7}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "61", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "16", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.1% over one week, -6.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today"}], "updated_at": "2026-06-22T22:50:29.022983+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}